Bayer's Avelox approved for Japanese markets

By E. Janene Geiss

Philadelphia, Oct. 21 - Bayer HealthCare AG's Japanese affiliate, Bayer Yukuhin Ltd., announced Friday that it was granted importing rights by the Japanese Ministry of Health, Labor and Welfare for the oral version of antibacterial Avelox for respiratory infections.

Bayer Yakuhin and Shionogi & Co. Ltd. signed an agreement in 2003 that provides Shionogi with exclusive Japanese marketing rights for Avelox.

According to the terms of the agreement, Bayer Yakuhin will continue to hold the drug's registration and Shionogi will exclusively market the product.

In a company news release, officials noted Japan is the world's second largest pharmaceutical market. The Japanese oral anti-infective market was worth more than €2 billion in 2004.

Recently, Avelox also received U.S. and European approvals for use in treating complicated skin and skin structure infections, officials said.

Avelox, or moxifloxacin hydrochloride, is now licensed in 104 countries around the world.

Bayer HealthCare AG, a subgroup of Bayer AG, is focused on developing products to improve human and animal health.

Bayer Yakuhin Ltd. is in charge of Japanese health care markets as part of the global operations of Bayer HealthCare AG.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.